CarolinaYan863

The researchers examined four drugs: Allegra, Arava, Amaryl and Zithromax. In the second half 2005, each of these drugs go out of patent protection. Their general equivalents were purchased alternatively at the average factor of 87 percent within 30 days of the equivalents distribution at pharmacies.

The study was prepared by Medco Health Solutions Inc. Situated in Frankin Lakes, which can be the largest drug profit management company in U.S. The company bargains for low rates of prescription drug on behalf of its customers.

According to the research, Zithromax, the hit of Pfizer Inc. with its annual sales of $1.85 billion was rapidly taken at pharmacies by equivalent at a 90 percent rate soon after it dropped its patent protection in November.

The research authors mentioned the replacement of Zithromax, an for respiratory infections, as proof that more and more doctors propose simple types of brand name drugs more quickly, even when it's about alleged acute treatment drugs, such as Zithromax.

The truly good news is that these four common medications are just the start. With numerous popular medications anticipated to go off patent within the next a long period, substantial prescription drug costs savings should be seen by us - said a senior vice president, Dr. Glen Stettin.

A speaker at Medco, Ann Smith stated that over 70 brand drugs, including 19 blockbusters, are losing their patent protection over the following five years - with total annually sales of $45 million.

If Medcos study reveals a trend, in the coming years consumers, employers and insurance companies helps you to save vast amounts of dollars in prescription drug - Smith said.

The data met with enthusiastic response from consumer groups.

Develop the trend continues. Its good for customers, revealed Bill Vaughan, senior policy analyst for an group, Consumer Union, based in Washington, D.C.

Vaughan mentioned that past doubts concerning the safety and effectiveness of generic drugs have apparently started to fade as society is becoming more concerned with rapid increase of health-care costs.

The FDA approves these generic drugs because they have been established just as safe and effective as their brand name counterparts, however, you spend a portion of the cost, Vaughan said. We think this really is very good and can save yourself consumers literally billions of dollars within the next couple of years.

At once, large pharmaceutical companies have said that their brand name drugs won't be replaced by reproductions as insurers and doctors know that the brand name drugs promise greater treatment and in consequence - save money.

Hank McKinnell, Pfizer Chairman used that argument all through last session with professionals in Nyc.

In the event that you dont just like the high cost of health care, try the high cost of nausea, McKinnell suggested. The researchers reviewed four drugs: Allegra, Arava, Amaryl and Zithromax. In the next 50% of 2005, each one of these drugs come to an end of patent protection. Their common equivalents were obtained alternatively at an average factor of 87 percent within 1 month of the equivalents delivery at pharmacies.

The investigation was prepared by Medco Health Solutions Inc. based in Frankin Lakes, which can be the biggest drug profit management company in U.S. The organization discounts for low rates of prescription drug on behalf of its clients.

Based on the research, Zithromax, the hit of Pfizer Inc. with its annual sales of $1.85 million was quickly substituted at pharmacies by generic equivalent at a 90 percent rate just after it dropped its patent protection in November.

The study authors mentioned the substitution of Zithromax, an for respiratory infections, as proof that more and more doctors recommend generic types of manufacturer drugs more easily, even when it's about so-called acute care drugs, such as Zithromax.

The really good news is that these four common medications are only the start. With numerous common medicines expected to move off patent next many years, we have to see substantial prescription drug prices savings - reported a senior vice president, Dr. Glen Stettin.

A speaker at Medco, Ann Smith reported that over 70 brand medications, including 19 blockbusters, are losing their patent protection over the following five years - with total annually sales of $45 billion.

If Medcos study shows a development, in the coming years customers, companies and insurance companies will save huge amounts of dollars in prescription drug - Smith said.

The information met with enthusiastic reaction from consumer groups.

We hope the pattern continues. Its good for consumers, confessed Bill Vaughan, senior coverage analyst for an group, Consumer Union, based in Washington, D.C.

Vaughan described that past fears concerning the safety and effectiveness of common drugs have apparently started to disappear as society is becoming more concerned with rapid increase of health-care costs.

The FDA approves these generic drugs simply because they have already been decided just as safe and effective as their brand name counterparts, but you spend a portion of the purchase price, Vaughan reported. We think that is very good and can save yourself people literally billions of dollars in the next several years.

At once, large pharmaceutical organizations have said that their brand name drugs will not be replaced by knockoffs as insurers and doctors understand that the brand name drugs assure greater treatment and in consequence - conserve money.

Hank McKinnell, Pfizer Chairman used that argument during last session with analysts in Nyc.

In the event that you dont like the high cost of medical care, try the high cost of illness, McKinnell advised.